[Federal Register Volume 72, Number 41 (Friday, March 2, 2007)]
[Notices]
[Pages 9540-9541]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-3695]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Identification and Isolation of the Receptor for Pigment Epithelium-
Derived Factor (PEDF)

    Description of Technology: This application describes and claims 
compositions and methods related to PEDF-R, a receptor for pigment 
epithelium-derived factor (PEDF). PEDF (aka serpin f1 gene product) is 
a protein, belonging to the serpin superfamily with neurotrophic, 
gliastatic, neuronotrophic, antiangiogenic, and antitumorigenic 
properties. However, PEDF lacks the characteristic ability of serpins 
to inhibit serine protease activity. In particular, the compositions 
and methods described and claimed in this application are related to 
the isolation, cloning, expression and characterization of a receptor 
for PEDF, PEDF-R. The PEDF-R gene (also known as TTS-2.2, iPLA-zeta, 
ATGL, desnutrin, or PNPLA2) is located on chromosome 11. The sequence 
of the PEDF-R polypeptide is composed of 504 amino acids, and shares 
homology with other genes such as for adiponutrin and GS2, contains a 
patatin-like phospholipase A2 domain and up to four transmembrane 
regions. PEDF-R exhibits a potent phospholipase A2 activity, binds to 
PEDF ligands with high affinity, and it localizes to plasma membranes. 
An extracellular loop region is available for the interactions with 
extracellular PEDF ligand, which stimulate the phospholipase activity 
of PEDF-R. The identification of this novel PEDF-R gene in the retina 
for a phospholipase-linked membrane protein with high affinity for 
PEDF, suggests a molecular pathway by which ligand/receptor interaction 
on the cell surface could generate a cellular signal.
    Applications:
    1. Basic research to further elucidate the role of PEDF and its 
receptor in signal transduction pathways.
    2. Development of drug screening assays to identify agonists and 
antagonists of PEDF activity.
    3. Development of new biological molecules to regulate PEDF 
signaling such as monoclonal antibodies and chimeric IgG-receptor 
constructs.
    Development Stage: Information on research being conducted in Dr. 
Becerra's laboratory can be found on the Internet at http://www.nei.nih.gov/intramural/protein_struct_func.asp. The ability of 
the receptor or receptor-targeted molecules and biologics to be used as 
therapeutics remains the subject of early research and development 
efforts.
    Inventors: S. Patricia Becerra (NEI), Luigi Notari (NEI), Jorge 
Laborda (CDER/FDA), et al.
    Publications:
    1. The patent application has been published as WO 2005/014645 A2 
on 17 Feb 2005.
    2. L Notari et al. Identification of a lipase-linked cell membrane 
receptor for pigment epithelium-derived factor. J Biol Chem. 2006 Dec 
8; 281(49):38022-38037.
    Patent Status:
    1. U.S. Patent Application No. 10/566,540 filed 16 Oct 2006, 
entitled ``PEDF-R Receptor and Uses,'' is pending (HHS Reference No. E-
314-2003/2-US-02). The U.S. Application has not been published. Only 
U.S. Patent protection has been sought for this technology. There are 
no foreign counterpart patent applications.
    2. PCT/US2004/025560 filed 05 Aug 2004 and published as WO 2005/
014645 A2 on 17 Feb 2005, now expired (HHS Reference No. E-314-2003/2-
PCT-01).
    3. U.S. Provisional Application No. 60/579,177 filed 12 Jun 2004, 
now abandoned (HHS Reference No. E-314-2003/1-US-01).
    4. U.S. Provisional Application No. 60/493,713 filed 07 Aug 2003, 
now abandoned (HHS Reference No. E-314-2003/0-US-01).

[[Page 9541]]

    Biological Materials Availability: Biological materials related to 
this technology are not available at this time.
    Licensing Availability: This application is available for license 
on a non-exclusive or exclusive basis.
    Licensing Contact: Susan S. Rucker; 301/435-4478; e-mail: 
<a href="/cdn-cgi/l/email-protection#c4b6b1a7afa1b6b7b184a9a5ada8eaaaadaceaa3abb2"><span class="__cf_email__" data-cfemail="a0d2d5c3cbc5d2d3d5e0cdc1c9cc8ecec9c88ec7cfd6">[email protected]</span></a>.

Genes Expressed in Prostate Cancer and Methods of Use

    Description of Technology: This invention is a novel gene, called 
New Gene Expressed in Prostate (NGEP). This gene appears to be 
expressed only in human prostate and prostate cancer. This gene has two 
known splice variants of significantly different size. The shorter 
splice variant encodes a cytoplasmic protein, while the longer splice 
variant encodes a plasma membrane protein, which has been detected on 
the plasma membrane of human cancer cells.
    This patent application contains claims to the polypeptide, NGEP, 
nucleotides encoding NGEP, antibodies that bind NGEP polypeptides, and 
methods of using these polypeptides, polynucleotides, and antibodies.
    The presence of the protein on the cell surface and the selective 
expression in prostate and prostate cancer make this a potential target 
for prostate cancer diagnostics and therapeutics. Potential 
therapeutics could be gene-based, vaccines, antibodies, or 
immunoconjugates.
    Inventors: Ira Pastan, Tapan Bera, and Byungkook Lee (NCI.)
    Publications:
    1. S Das et al. NGEP, a prostate-specific plasma membrane protein 
that promotes the association of LNCaP cells. Cancer Res. 2007 Feb 15; 
67(4):1594-1601.
    2. TK Bera et al. NGEP, a gene encoding a membrane protein detected 
only in prostate cancer and normal prostate. Proc Natl Acad Sci USA. 
2004 Mar 2; 101(9):3050-3064.
    Patent Status:
    1. U.S. Provisional Application No. 60/461,399 filed 08 Apr 2003 
(HHS Reference No. E-148-2003/0-US-01).
    2. PCT Application No. PCT/US04/10588 filed 05 Apr 2004, which 
published as WO 2004/092213 on 28 Oct 2004 (HHS Reference No. E-148-
2003/0-PCT-02).
    3. U.S. Patent Application No. 10/552,515 filed 06 Oct 2005 (HHS 
Reference No. E-148-2003/0-US-03).
    Licensing Status: Available for non-exclusive licensing.
    Licensing Contact: Jesse S. Kindra, J.D.; 301/435-5559; 
<a href="/cdn-cgi/l/email-protection#a2c9cbccc6d0c3c8e2cfc3cbce8ccccbca8cc5cdd4"><span class="__cf_email__" data-cfemail="85eeecebe1f7e4efc5e8e4ece9abebecedabe2eaf3">[email protected]</span></a>.

    Dated: February 22, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E7-3695 Filed 3-1-07; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>